These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8722119)

  • 1. Apparent stimulation of thrombopoesis with interleukin-3 (IL-3) in chemotherapy induced myelosuppression.
    Schweiger C; Färber L; Füchsel G; Heinrich D; Meinerz W
    Biofactors; 1995-1996; 5(2):73-4. PubMed ID: 8722119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficiency, safety and tolerability of recombinant human interleukin-3 (rhIL-3) as supportive therapy accompanying dose-intensive carboplatin containing chemotherapy in ovarian cancer with special regard to thrombocytopenia].
    Meden H; Fock M; Krauss T; Kuhn W
    Zentralbl Gynakol; 1999; 121(8):375-83. PubMed ID: 10486880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant human interleukin-3 (rhIL-3) on persisting chemotherapy-induced thrombocytopenia.
    Meden H; Fock M; Kuhn W
    Anticancer Drugs; 1994 Aug; 5(4):483-6. PubMed ID: 7949256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
    Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma.
    Hofstra LS; Kristensen GB; Willemse PH; Vindevoghel A; Meden H; Lahousen M; Oberling F; Sorbe B; Crump M; Sklenar I; Sluiter WJ; Kiese B; Trope CG; de Vries EG
    J Clin Oncol; 1998 Oct; 16(10):3335-44. PubMed ID: 9779710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor).
    Kaye JA
    Stem Cells; 1996; 14 Suppl 1():256-60. PubMed ID: 11012229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and safety of rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia].
    Li L; Xu CG; Wang XW; Guo QS; Sun YH; Sun LM
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):377-9. PubMed ID: 16117904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
    Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
    Lei W; Liang J; Chen WG; Ma XZ; Xu M; Du LL
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):542-4. PubMed ID: 17147124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer.
    Biesma B; Willemse PH; Mulder NH; Sleijfer DT; Gietema JA; Mull R; Limburg PC; Bouma J; Vellenga E; de Vries EG
    Blood; 1992 Sep; 80(5):1141-8. PubMed ID: 1515636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
    Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy and mechanism of rhIL-11 in the management of chemotherapy-induced thrombocytopenia in acute leukemia].
    Cui XL; Wang L; Gao J; Qin P; Shi Y; Peng J; Hou M
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):345-7. PubMed ID: 16185478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of prolonged chemotherapy induced severe thrombocytopenia with recombinant human interleukin-3--a report on four cases.
    Färber L; Haus U; Füchsel G; Theml H; Chatsiproios D; Schmid H; Burger KJ; Drechsler S
    Anticancer Drugs; 1997 Mar; 8(3):288-92. PubMed ID: 9095335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
    Sun XF; Guan ZZ; Huang H; Zhou QH; Yi C; Zhang LJ; Zhu J; Li R; Zhou J; Zhang M; Guo Y
    Ai Zheng; 2002 Aug; 21(8):892-5. PubMed ID: 12478901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy.
    Cantor SB; Elting LS; Hudson DV; Rubenstein EB
    Cancer; 2003 Jun; 97(12):3099-106. PubMed ID: 12784347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia.
    Vadhan-Raj S; Patel S; Bueso-Ramos C; Folloder J; Papadopolous N; Burgess A; Broemeling LD; Broxmeyer HE; Benjamin RS
    J Clin Oncol; 2003 Aug; 21(16):3158-67. PubMed ID: 12915607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
    Dercksen MW; Hoekman K; ten Bokkel Huinink WW; Rankin EM; Dubbelman R; van Tinteren H; Wagstaff J; Pinedo HM
    Br J Cancer; 1993 Nov; 68(5):996-1003. PubMed ID: 7692922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells.
    Saitoh M; Taguchi K; Momose K; Suga K; Yamazaki N; Ono C; Suzuki T; Takeuchi O; Yasuda S; Miyata K
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):161-6. PubMed ID: 11862431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-3 in hematology and oncology: current state of knowledge and future directions.
    Mangi MH; Newland AC
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):87-95. PubMed ID: 10515681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.